Kuste Biopharma initiates its first clinical trial
Kuste is excited to initiate the first clinical trial with our proprietary anti-inflammatory drug Brimapitide (KU002), exploring the safety and efficacy in patients who suffer from Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
The study has gained approval from the Health Authority and Ethics Committees in The Netherlands, where patient recruitment is currently ongoing and will take place in up to three sites.
The study is planned to be conducted also in other sites in Europe: Belgium and Sweden, following the approval from the respective Health Authority and Ethics Committee.
For more information about Interstitial cystitis:
